Press Release Details
Twist Bioscience to Highlight Genotyping by Sequencing and Methylation Solution During AGBT
-- Virtual Poster Presentation, Customer Talks, Booth Available --
During the conference, Twist will host a workshop with customer presentations from Regeneron Genetics Center and HelioHealth; Twist will present a poster detailing the ongoing development of its
Date:
“Believe in Better - an update from Twist” -- Emily Leproust, Ph.D., CEO and co-founder of
“No more arrays: genotyping by sequencing enables economical and improved association studies” --
“NGS Methylation in Cancer Detection” --
Date:
Poster Session
Abstract: Increasing the throughput of NGS sequencing through rational design and empirical validation of 10,000 Unique Dual Indexes (UDI). To assess the performance of individual barcodes to increase the throughput of NGS sequencing, Twist developed Artificial Barcoded Libraries (ABLs), a high throughput NGS library generation method that utilizes fragmentation of a human genomic source and automation to generate thousands of unique NGS libraries with minimal bias. The approach yielded more than 10,000 pairs of 12bp UDI primers. Performance criteria for uniform UDI primer sets with thousands of members that are suitable for high multiplex hybridization applications and investigations are presented.
Presenter:
About
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005260/en/
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com
Source: